Inflazyme preclinical data

IZP (Vancouver) announced that IZP-94005 showed efficacy in in vitro models that use human tissues and leukocytes. The agent prevents leukocyte activation by crystals produced in arthritic tissues, as judged by the production of oxygen radicals, and lysosomal enzymes. It also prevents interleukin production in response to tumor necrosis factor and histamine. ...